| Document |
Document Title |
|
WO/2017/070464A1 |
Compounds having methyltransferase inhibitory activity are disclosed. The compounds have the structure (I) They are useful in the treatment of cancer and similar diseases associated with inappropriate methyltransferase activity.
|
|
WO/2017/066791A1 |
The present disclosure relates to cap analogs of formula (I), which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for prepar...
|
|
WO/2017/066571A1 |
Provided are methods and compositions for treating cancers in patients carrying an IDHl mutation using a combination of an inhibitor of a mutant IDHl enzyme and a DNA demethylating agent.
|
|
WO/2017/066566A1 |
Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation using a combination of an inhibitor of a mutant IDH1 enzyme and an AML induction and consolidation therapy.
|
|
WO/2017/066793A1 |
The present disclosure relates to cap analogs of formula (I) as defined in claim 1, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to met...
|
|
WO/2017/066782A1 |
The present disclosure relates to cap analogs of formula (I), which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for prepar...
|
|
WO/2017/059249A1 |
The invention relates to crystalline forms of a β-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterin...
|
|
WO/2017/058953A1 |
Disclosed herein, inter alia, are compounds, compositions, and methods of use thereof in the sequencing a nucleic acid.
|
|
WO/2017/053216A2 |
The present invention is directed to 4'-substituted nucleoside derivatives of Formula (I) and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the proph...
|
|
WO/2017/045583A1 |
Provided is a preparation method of composition rich in compound Sp-1. The method performs isomer separation on a reaction product from a first step, and then performs a two-step chemical synthesis, so as to prepare a composition compris...
|
|
WO/2017/045582A1 |
Provided in the present invention are a novel preparation method of nucleoside phosphoramidate prodrugs and intermediates thereof. In particular, the method is adopted to perform isomer separation on a reaction product from a first step ...
|
|
WO/2017/048147A1 |
The object of the invention is a method of synthesis and purification of a nucleoside and/or a nucleotide being a mono-, di- or triphosphate, wherein a Huisgen' s azide-alkyne cycloaddition reaction is being performed using a compound of...
|
|
WO/2017/045581A1 |
The present invention involves a composition rich in compound 61501b, wherein the compound 61501b has a purity not less than 90% or more. The composition has a significant advantage in preparing high-purity compound Sp-1. In addition, th...
|
|
WO/2017/047816A1 |
The present invention provides a method for producing guanidine crosslinked artificial nucleic acid (abbreviated hereinafter as GuNA), and an intermediate compound for the production thereof. Specifically, the present invention provides ...
|
|
WO/2017/042038A1 |
The present disclosure relates to compositions and methods based on polypeptide-tagged nucleotide, and the use of such polypeptide-tagged nucleotides in nanopore devices and methods.
|
|
WO/2017/040896A1 |
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...
|
|
WO/2017/040766A1 |
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...
|
|
WO/2017/040895A1 |
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...
|
|
WO/2017/040898A1 |
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...
|
|
WO/2017/036356A1 |
Provided are a new crystal form of Fludarabine Phosphat, a preparation method therefor, a pharmaceutical composition containing same, and an application thereof in preparing medicine. Crystal forms I and II of the Fludarabine Phosphat ha...
|
|
WO/2017/040892A1 |
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...
|
|
WO/2017/040899A2 |
|
|
WO/2017/040889A1 |
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...
|
|
WO/2017/035453A1 |
The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods useful for treating solid tumors. In a specific embodiment, a method for treating a solid tumor in a patient...
|
|
WO/2017/031278A1 |
The present disclosure relates to processes for inverting oligonucleotide probes in an in situ synthesized array. These processes can be used to reverse the orientation of probes with respect to the substrate from 3 '-bound to 5 '-bound....
|
|
WO/2017/027980A1 |
There is provided a method for treating or preventing a Neisseria gonorrhoeae infection in a subject, comprising administering to the subject an effective amount of a compound of general formula I below or a pharmaceutical composition co...
|
|
WO/2017/029408A1 |
Disclosed are solid state forms of sofosbuvir. The solid state forms may be co-crystals of sofosbuvir with at least one co-crystal former.
|
|
WO/2017/031189A1 |
The invention provides compositions and methods for the production of TDP-deoxysugars.
|
|
WO/2017/023687A1 |
In one aspect, the present invention features a method of inhibiting proliferation and/or reducing survival of a cell comprising a GNAQ polynucleotide or polypeptide having a R183Q or Q209L mutation, comprising contacting the cell with p...
|
|
WO/2017/024310A1 |
The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rc and A are defined herein. Also pr...
|
|
WO/2017/023694A1 |
This invention relates the use of Cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neop...
|
|
WO/2017/019581A1 |
The present invention is directed to processes for making Compounds of Formula (IV): (IV) and salts thereof, wherein B, X, R1, R2, R3 and R4 are defined herein.
|
|
WO/2017/018360A1 |
Provided is an artificial nucleoside, or artificial nucleotide, that is a compound represented by formula (I) or a salt thereof. In formula (I), Bx is a pyrimidine base, thioxopyrimidine base, or purine base, R1, R2, R3 and R4 are hydrog...
|
|
WO/2017/019918A1 |
Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and thera...
|
|
WO/2017/009746A1 |
The present invention relates to an improved process for the preparation Sofosbuvir Formula (I). The present further relates to Sofosbuvir having a purity of greater than 99.5%.
|
|
WO/2017/001307A1 |
The present invention relates to compounds of formula (I), wherein R1 to R4 are as described herein, and their pharmaceutically acceptable salts, enantiomers or diastereomers thereof, and compositions including the compounds for use in t...
|
|
WO/2017/004261A1 |
The present disclosure provides compounds comprising modified oligonucleotides for use in CRISPR. In certain embodiments, such modified oligonucleotides provide improved properties of crRNA. In cetain embodiments, such modified oligonucl...
|
|
WO/2017/004203A1 |
In certain embodiments, a method of detection includes providing cells labeled with a first element tag bound to a target RNA sequence and a second element tag bound to a target protein. The method may further include ionizing a cell, or...
|
|
WO/2017/004499A1 |
This invention relates to compositions and methods for the treatment of infection such as RSV, influenza, adenovirus, or rhinovirus.
|
|
WO/2016/210232A1 |
Topical compositions comprising niacinamide mononucleotide to improve the appearance of aging skin and to prevent and treat skin aging; and methods of use of topical compositions comprising niacinamide mononucleotide to improve the appea...
|
|
WO/2016/178876A9 |
The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV, HEV, and influenza infection ...
|
|
WO/2016/200447A1 |
Compositions containing a combination of nicotinamide riboside and pterostilbene for treating skin disorders, and methods of treating skin disorders using these compositions and their equivalents are described. The skin disorders that ar...
|
|
WO/2016/201374A1 |
Described herein are sulfamide adenosine derivatives of Formula (I) or (II), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods, uses, and kits involving the inventive compounds or p...
|
|
WO/2016/201025A1 |
Provided herein are photocrosslinking reagents, crosslinkable proteins displaying photocrosslinking groups, crosslinked protein-protein complexes, and methods of use thereof.
|
|
WO/2016/198948A1 |
Enzyme-based systems and methods for synthesizing the NAD precursors NMN and NaMN are disclosed. Such methods and systems utilize a mutated form of phosphoribosylpyrophosphate synthetase (PRS) that is superactive and/or other enzyme or e...
|
|
WO/2016/195353A1 |
The present invention provides to a cytidine deaminase (CDA)-resistant compound selected from the group consisting of 1'-cyano-cytarabine, 1'-cyano-gemcitabine, 1'-cyano-5-azacytidine and 1'-cyano-5-aza-2'-deoxycytidine, a prodrug or an ...
|
|
WO/2016/196735A2 |
The present disclosure provides new procedures and intermediates for the preparation of Sofosbuvir.
|
|
WO/2016/188943A1 |
The present invention relates to novel nucleoside derivatives of formula (I) as defined in claim 1, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.
|
|
WO/2016/188868A1 |
The invention relates to new nucleoside-lipid compounds with pH-sensitive dialkylorthoesterchains, to the process for their preparation and to their uses, in particular their use for transportation or vectorization of at least one therap...
|
|
WO/2016/189040A1 |
A process for preparing a nucleoside phosphoramidate, in particular to a process for preparing sofosbuvir, wherein a phosphoramidate derivative is used as starting material.
|
